FTC Study Finds Pharmaceutical Industry Continued to Make Numerous Business Deals that Delay Consumers’ Access to Lower-Cost Generic Drugs

FTC Chairman Asks Congressional Supercommittee to Reduce the Deficit and Lower Nation’s Health Care Costs by Restricting Pay-for-Delay Deals

Washington, DC–(ENEWSPF)–October 25, 2011.  According to an overview of industry data released by the staff of the Federal Trade Commission, in Fiscal Year 2011, pharmaceutical companies continued a recent anticompetitive trend of paying potential generic rivals to delay the introduction of lower-cost prescription drug alternatives for American consumers.

The FTC staff reportfound that drug companies…